Fannin Partners

Fannin Partners operates as an early-stage life sciences product development studio, advancing pharmaceutical and medical device assets. Based in Houston, it actively manages the de-risking and commercialization of promising innovations. The company primarily in-licenses novel small molecules and medical technologies demonstrating in-vivo efficacy, targeting validated biological pathways.

Co-founded in 2014 by Chairman Leo Linbeck III and Managing Partner Dr. Atul Varadhachary, Fannin Partners arose from a key insight. They identified the significant gap between academic life science discoveries from institutions like the Texas Medical Center and their commercial translation. This established their systematic studio model for nurturing early ventures.

Fannin Partners collaborates with academic inventors and research institutions, commercializing scientific breakthroughs. Its mission is to accelerate the development of early-stage pharmaceutical and medical device assets. The company ultimately aims to address vital unmet medical needs by transitioning innovative solutions from research to patient applications.